All Insights
Showing 1 - 12 of 239
Artificial intelligence
High-risk AI systems in life sciences face strict regulatory scrutiny from new EU rules
Businesses should consider if and how AI is used internally or externally and get ready for the risk-based approach
Artificial intelligence
New AI legislation's reach extends into European healthcare
What impact could the sector-neutral EU AI Act have on public health and patient care across Europe?
Intellectual property
The UK is developing its approach to deregulating gene editing in plants
The UK has pursued a post-Brexit deregulatory agenda via new legislation but has it failed to capitalise on the changes?
Artificial intelligence
New EU AI Act is poised to shape the future for life sciences in Europe
What is the extent of the sector's application of AI and the regulatory outlook following European Parliament approval?
Regulatory and compliance
European Parliament formally adopts Product Liability Directive
What changes and practical actions should businesses be considering?
International expansion and growth
Setting sail globally: launching internationally in an interconnected world
Launching a business internationally can be a game-changer but comes with its own set of challenges and considerations
Regulatory and compliance
UK government unveils draft procurement regulations for public sector bids
Authorities and suppliers will need to keep an eye on information published about procurements and resulting contracts
Life Sciences and Healthcare
Decision time for UK medical device regulation: diverge or converge with the EU?
The MHRA appears to be considering an approach for UK regulations that would broadly mirror the EU model
Life Sciences and Healthcare
Medication advertising in the digital age
The Generalitat of Catalonia has updated its guide to advertising medicines for human use with a focus on digital advertising
Intellectual property
What qualifies as a legitimate reason to object to parallel trade of medicines in Europe?
Trade mark owners are able to object to the parallel trade of medicines provided that there are legitimate reasons
Intellectual property
What are the patentability implications of deregulating gene editing in plants in the EU?
The European Parliament has voted to embrace more flexibility in the regulation of gene-edited plants but has proposed a ban
Life Sciences and Healthcare
Navigating Belgium's life sciences terrain: a strategic overview
Insights into regulations, trends, and strategic pathways for the pharmaceutical, medical device and food (supplement) industries